Loading...

Synthetic MR

OTCPK:SYNM.F
Snowflake Description

Exceptional growth potential with flawless balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SYNM.F
OTCPK
SEK1B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Synthetic MR AB (publ) develops and markets software solutions for magnetic resonance imaging (MRI) in Sweden and internationally. The last earnings update was 59 days ago. More info.


Add to Portfolio Compare Print
SYNM.F Share Price and Events
7 Day Returns
0%
OTCPK:SYNM.F
-2%
US Healthcare Services
-0.4%
US Market
1 Year Returns
-
OTCPK:SYNM.F
28.4%
US Healthcare Services
4.3%
US Market
SYNM.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Synthetic MR (SYNM.F) 0% 0% - - - -
US Healthcare Services -2% 3.7% 17.2% 28.4% 72.6% 63.2%
US Market -0.4% 2.8% 2.7% 4.3% 40.9% 38.2%
1 Year Return vs Industry and Market
  • No trading data on SYNM.F.
  • No trading data on SYNM.F.
Price Volatility
SYNM.F
Industry
5yr Volatility vs Market

Value

 Is Synthetic MR undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Synthetic MR to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Synthetic MR.

OTCPK:SYNM.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:SYNM.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.1
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.104 (1 + (1- 22%) (0%))
1.07
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.07
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.07 * 5.96%)
9.1%

Discounted Cash Flow Calculation for OTCPK:SYNM.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Synthetic MR is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:SYNM.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 9.1%)
2019 20.00 Analyst x1 18.33
2020 30.00 Analyst x1 25.20
2021 48.00 Analyst x1 36.96
2022 75.00 Analyst x1 52.93
2023 97.82 Est @ 30.43% 63.27
2024 119.46 Est @ 22.12% 70.82
2025 138.93 Est @ 16.3% 75.49
2026 155.93 Est @ 12.23% 77.66
2027 170.55 Est @ 9.38% 77.85
2028 183.15 Est @ 7.39% 76.62
Present value of next 10 years cash flows SEK575.13
OTCPK:SYNM.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK183.15 × (1 + 2.73%) ÷ (9.1% – 2.73%)
SEK2,951.45
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK2,951.45 ÷ (1 + 9.1%)10
SEK1,234.80
OTCPK:SYNM.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK575.13 + SEK1,234.80
SEK1,809.93
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK1,809.93 / 4.04
SEK447.99
OTCPK:SYNM.F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:SYNM.F represents 0.10886x of NGM:SYNT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.10886x
Value per Share
(Listing Adjusted, USD)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 447.99 x 0.10886
$48.77
Value per share (USD) From above. $48.77
Current discount Discount to share price of $29.50
= -1 x ($29.50 - $48.77) / $48.77
39.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Synthetic MR is available for.
Intrinsic value
40%
Share price is $29.5 vs Future cash flow value of $48.77
Current Discount Checks
For Synthetic MR to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Synthetic MR's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Synthetic MR's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Synthetic MR's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Synthetic MR's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:SYNM.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in SEK SEK3.49
NGM:SYNT Share Price ** NGM (2019-05-16) in SEK SEK271
United States of America Healthcare Services Industry PE Ratio Median Figure of 13 Publicly-Listed Healthcare Services Companies 57.1x
United States of America Market PE Ratio Median Figure of 3,094 Publicly-Listed Companies 17.77x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Synthetic MR.

OTCPK:SYNM.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NGM:SYNT Share Price ÷ EPS (both in SEK)

= 271 ÷ 3.49

77.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synthetic MR is overvalued based on earnings compared to the US Healthcare Services industry average.
  • Synthetic MR is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Synthetic MR's expected growth come at a high price?
Raw Data
OTCPK:SYNM.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 77.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
41.6%per year
United States of America Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2.57x
United States of America Market PEG Ratio Median Figure of 2,133 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

OTCPK:SYNM.F PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 77.59x ÷ 41.6%

1.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synthetic MR is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Synthetic MR's assets?
Raw Data
OTCPK:SYNM.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in SEK SEK11.95
NGM:SYNT Share Price * NGM (2019-05-16) in SEK SEK271
United States of America Healthcare Services Industry PB Ratio Median Figure of 36 Publicly-Listed Healthcare Services Companies 5.25x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.78x
OTCPK:SYNM.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NGM:SYNT Share Price ÷ Book Value per Share (both in SEK)

= 271 ÷ 11.95

22.67x

* Primary Listing of Synthetic MR.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synthetic MR is overvalued based on assets compared to the US Healthcare Services industry average.
X
Value checks
We assess Synthetic MR's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Synthetic MR has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Synthetic MR expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Synthetic MR expected to grow at an attractive rate?
  • Synthetic MR's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Synthetic MR's earnings growth is expected to exceed the United States of America market average.
  • Synthetic MR's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:SYNM.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:SYNM.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 41.6%
OTCPK:SYNM.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 29.5%
United States of America Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 24.3%
United States of America Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 11.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:SYNM.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:SYNM.F Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 148 81 77 1
2021-12-31 124 54 55 2
2020-12-31 89 34 36 2
2019-12-31 62 24 21 2
OTCPK:SYNM.F Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-03-31 50 21 14
2018-12-31 51 18 15
2018-09-30 49 19 14
2018-06-30 45 15 12
2018-03-31 39 14 8
2017-12-31 38 11 8
2017-09-30 34 11 8
2017-06-30 30 9 7
2017-03-31 28 6 6
2016-12-31 22 4 2
2016-09-30 15 0 1
2016-06-30 14 -1 4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Synthetic MR's earnings are expected to grow significantly at over 20% yearly.
  • Synthetic MR's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:SYNM.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Synthetic MR Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:SYNM.F Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 19.10 19.10 19.10 1.00
2021-12-31 13.45 14.41 12.50 2.00
2020-12-31 8.85 9.81 7.88 2.00
2019-12-31 5.18 5.48 4.89 2.00
OTCPK:SYNM.F Past Financials Data
Date (Data in SEK Millions) EPS *
2019-03-31 3.49
2018-12-31 3.63
2018-09-30 3.50
2018-06-30 2.88
2018-03-31 2.08
2017-12-31 2.07
2017-09-30 2.02
2017-06-30 1.66
2017-03-31 1.55
2016-12-31 0.59
2016-09-30 0.31
2016-06-30 0.88

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Synthetic MR is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Synthetic MR's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Synthetic MR has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Synthetic MR performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Synthetic MR's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Synthetic MR has delivered over 20% year on year earnings growth in the past 5 years.
  • Synthetic MR's 1-year earnings growth is less than its 5-year average (67.5% vs 69.2%)
  • Synthetic MR's earnings growth has exceeded the US Healthcare Services industry average in the past year (67.5% vs 22%).
Earnings and Revenue History
Synthetic MR's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Synthetic MR Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:SYNM.F Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 50.42 14.11 20.46
2018-12-31 50.73 14.65 19.37
2018-09-30 48.52 14.15 17.71
2018-06-30 44.95 11.64 17.19
2018-03-31 39.41 8.42 16.02
2017-12-31 37.92 8.36 15.67
2017-09-30 34.18 8.15 14.59
2017-06-30 30.35 6.72 13.44
2017-03-31 28.35 6.27 12.42
2016-12-31 22.15 2.39 11.75
2016-09-30 15.40 1.25 8.69
2016-06-30 14.19 3.55 8.02
2016-03-31 11.35 1.46 8.89
2015-12-31 9.21 0.08 9.30
2015-09-30 7.14 -4.28 12.08
2015-06-30 5.06 -8.63 11.19
2015-03-31 4.72 -7.62 9.96
2014-12-31 4.38 -6.61 8.74
2014-09-30 4.87 -6.01 8.56
2014-06-30 4.85 -5.06 7.67
2014-03-31 4.66 -4.89 7.11
2013-12-31 4.47 -4.73 6.55
2013-09-30 4.11 -4.34 5.92
2012-12-31 2.71 -4.07 5.33

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Synthetic MR has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Synthetic MR used its assets more efficiently than the US Healthcare Services industry average last year based on Return on Assets.
  • Synthetic MR has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Synthetic MR's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Synthetic MR has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Synthetic MR's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Synthetic MR's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Synthetic MR is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Synthetic MR's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Synthetic MR's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Synthetic MR has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Synthetic MR Company Filings, last reported 2 months ago.

OTCPK:SYNM.F Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 48.29 0.00 39.23
2018-12-31 46.06 0.00 32.09
2018-09-30 41.61 0.00 30.84
2018-06-30 37.39 0.00 24.46
2018-03-31 34.18 0.00 20.96
2017-12-31 32.23 0.00 16.99
2017-09-30 28.28 0.00 14.58
2017-06-30 26.58 0.00 12.67
2017-03-31 26.57 0.00 10.17
2016-12-31 23.87 0.00 9.32
2016-09-30
2016-06-30 19.85 0.00 6.57
2016-03-31 21.47 0.00 8.20
2015-12-31 21.47 0.00 8.20
2015-09-30 21.47 0.00 8.20
2015-06-30 16.30 0.00 10.80
2015-03-31 21.39 0.00 15.93
2014-12-31 21.39 0.00 15.93
2014-09-30 21.39 0.00 15.93
2014-06-30 10.11 0.00 4.50
2014-03-31 13.19 0.00 7.12
2013-12-31 13.19 0.00 7.12
2013-09-30 14.42 0.02 9.20
2012-12-31 7.63 0.00 3.53
  • Synthetic MR has no debt.
  • Synthetic MR had no debt 5 years ago.
  • Synthetic MR has no debt, it does not need to be covered by operating cash flow.
  • Synthetic MR has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Synthetic MR's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Synthetic MR has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Synthetic MR's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.55%
Current annual income from Synthetic MR dividends. Estimated to be 1.46% next year.
If you bought $2,000 of Synthetic MR shares you are expected to receive $11 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Synthetic MR's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
  • Synthetic MR's dividend is below the markets top 25% of dividend payers in United States of America (3.73%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:SYNM.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 15 Stocks 1.1%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:SYNM.F Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 7.72 1.00
2021-12-31 4.94 2.00
2020-12-31 3.19 2.00
2019-12-31 1.89 2.00
OTCPK:SYNM.F Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-04-08 1.500 0.507
2019-02-27 1.500 0.473

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synthetic MR is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
  • Synthetic MR is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Synthetic MR's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Synthetic MR's dividends as it is not paying a notable one for United States of America.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.6x coverage).
X
Income/ dividend checks
We assess Synthetic MR's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Synthetic MR afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Synthetic MR has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Synthetic MR's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Fredrik Jeppsson
AGE 36
TENURE AS CEO 0.2 years
CEO Bio

Mr. Fredrik Jeppsson has been an Acting CEO of Synthetic MR AB (publ) since April 30, 2019. Mr. Jeppsson serves as the CFO of Synthetic MR AB (publ) and has been its Head of Investor Relations since June 30, 2017. Mr. Jeppsson was most recently Group Business Controller at Teracom, Boxer Group. Previously, he worked as an Authorized Accountant at PwC, which included responsibility for audits of listed companies.

CEO Compensation
  • Insufficient data for Fredrik to compare compensation growth.
  • Insufficient data for Fredrik to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

Bertus Warntjes

TITLE
Head of Innovation & Director
COMPENSATION
SEK928K
AGE
45
TENURE
1.4 yrs

Fredrik Jeppsson

TITLE
Acting CEO
AGE
36
TENURE
0.2 yrs

Jonas Hurtig

TITLE
Head of Marketing & Commercial Affairs
AGE
47

Lisa Warnroth

TITLE
Head of QA/RA
AGE
37

Markus Malmgren

TITLE
Head of Research & Development
AGE
40
Board of Directors Tenure

Average tenure and age of the Synthetic MR board of directors in years:

7.2
Average Tenure
57.5
Average Age
  • The tenure for the Synthetic MR board of directors is about average.
Board of Directors

Staffan Persson

TITLE
Chairman of the Board
COMPENSATION
SEK206K
AGE
62
TENURE
6 yrs

Bertus Warntjes

TITLE
Head of Innovation & Director
COMPENSATION
SEK928K
AGE
45
TENURE
12.4 yrs

Johan Sedihn

TITLE
Director
COMPENSATION
SEK133K
AGE
53
TENURE
8.4 yrs

Yvonne Mårtensson

TITLE
Director
COMPENSATION
SEK133K
AGE
65
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
28. Feb 19 Buy Yvonne Mårtensson Individual 27. Feb 19 27. Feb 19 2,000 $32.17 $64,332
22. Jan 19 Sell Staffan Persson Individual 21. Jan 19 21. Jan 19 -30,000 $33.28 $-998,259
X
Management checks
We assess Synthetic MR's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Synthetic MR has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Synthetic MR AB (publ) develops and markets software solutions for magnetic resonance imaging (MRI) in Sweden and internationally. The company offers SyMRI IMAGE, a software solution that optimizes MRI workflows and short scan times using synthetic MRI, as well as allows high patient throughput; magnetic resonance image compilation solutions; and SyMRI NEURO, which provides conventional MRI images for analysis and objective decision support for the diagnosis and follow-up of patients. It also offers SyMRI REMyDI that provides automatic measurement of myelin volume; and SyMRI research edition, which includes exportable SyMaps, parametric T1, T2, and PD maps. The company was founded in 2007 and is based in Linköping, Sweden. Synthetic MR AB (publ) is a subsidiary of Accelerator Nordic AB.

Details
Name: Synthetic MR AB (publ)
SYNM.F
Exchange: OTCPK
Founded: 2007
SEK121,694,614
4,040,078
Website: http://www.syntheticmr.com
Address: Synthetic MR AB (publ)
Storgatan 11,
Linköping,
Östergötland County, 582 23,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NGM SYNT Share Capital Nordic Growth Market SE SEK 18. Oct 2013
OTCPK SYNM.F Share Capital Pink Sheets LLC US USD 18. Oct 2013
LSE 0G79 Share Capital London Stock Exchange GB SEK 18. Oct 2013
Number of employees
Current staff
Staff numbers
19
Synthetic MR employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/27 00:52
End of day share price update: 2019/05/16 00:00
Last estimates confirmation: 2019/05/18
Last earnings filing: 2019/04/29
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.